JP2016053040A5 - - Google Patents

Download PDF

Info

Publication number
JP2016053040A5
JP2016053040A5 JP2015201153A JP2015201153A JP2016053040A5 JP 2016053040 A5 JP2016053040 A5 JP 2016053040A5 JP 2015201153 A JP2015201153 A JP 2015201153A JP 2015201153 A JP2015201153 A JP 2015201153A JP 2016053040 A5 JP2016053040 A5 JP 2016053040A5
Authority
JP
Japan
Prior art keywords
relaxin
risk
mortality
composition
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015201153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016053040A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016053040A publication Critical patent/JP2016053040A/ja
Publication of JP2016053040A5 publication Critical patent/JP2016053040A5/ja
Pending legal-status Critical Current

Links

JP2015201153A 2008-05-16 2015-10-09 急性心不全に伴う呼吸困難のリラキシンによる治療 Pending JP2016053040A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US12788908P 2008-05-16 2008-05-16
US61/127,889 2008-05-16
US19054508P 2008-08-28 2008-08-28
US61/190,545 2008-08-28
US20124008P 2008-12-08 2008-12-08
US61/201,240 2008-12-08
US16433309P 2009-03-27 2009-03-27
US61/164,333 2009-03-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014165276A Division JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療

Publications (2)

Publication Number Publication Date
JP2016053040A JP2016053040A (ja) 2016-04-14
JP2016053040A5 true JP2016053040A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-07-07

Family

ID=40834101

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011509783A Expired - Fee Related JP5651586B2 (ja) 2008-05-16 2009-05-15 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2012200728A Expired - Fee Related JP5638044B2 (ja) 2008-05-16 2012-09-12 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2014165276A Expired - Fee Related JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2015201153A Pending JP2016053040A (ja) 2008-05-16 2015-10-09 急性心不全に伴う呼吸困難のリラキシンによる治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011509783A Expired - Fee Related JP5651586B2 (ja) 2008-05-16 2009-05-15 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2012200728A Expired - Fee Related JP5638044B2 (ja) 2008-05-16 2012-09-12 急性心不全に伴う呼吸困難のリラキシンによる治療
JP2014165276A Expired - Fee Related JP5875646B2 (ja) 2008-05-16 2014-08-14 急性心不全に伴う呼吸困難のリラキシンによる治療

Country Status (30)

Country Link
US (7) US8415301B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP2829280A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (4) JP5651586B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (3) CN102036679A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR071810A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2009246114B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0913011A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2724540C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR11749A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1116925T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2288373T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA022948B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2546287T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB2462221B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1202054A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20150845T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE025483T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (3) IL208992A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA32389B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2010012450A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (2) MY159803A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (3) NZ589009A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2288373T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2288373E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (2) SG10201609580YA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2288373T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI386202B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA99953C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2009140659A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201007449B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2288373E (pt) 2008-05-16 2015-10-19 Corthera Inc Método de tratamento da dispneia associado com insuficiência cardíaca aguda
MX2010012502A (es) * 2008-05-16 2011-04-11 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
ES2541301T3 (es) 2010-03-10 2015-07-17 The University Of Melbourne Modulación de acuaporinas con relaxina
WO2012017071A1 (en) * 2010-08-06 2012-02-09 Pronota N.V. Perlecan as a biomarker for renal dysfunction
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (hu) 2010-08-17 2021-12-28 Ambrx Inc Módosított relaxin polipeptidek és felhasználásuk
KR20140054009A (ko) * 2011-07-01 2014-05-08 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신 융합 폴리펩타이드 및 그의 용도
WO2013059879A1 (en) * 2011-10-26 2013-05-02 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
PL2814513T3 (pl) * 2012-02-14 2018-06-29 The Regents Of The University Of California Układowe dostarczanie i regulowana ekspresja genów parakrynnych w chorobach sercowo-naczyniowych i innych stanach
US9452973B2 (en) 2012-05-04 2016-09-27 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Modulators of the relaxin receptor 1
ES2671639T3 (es) 2012-10-26 2018-06-07 Chiesi Farmaceutici S.P.A. Métodos para controlar la presión arterial y reducir la disnea en la insuficiencia cardiaca
CA2908935C (en) 2013-04-05 2021-06-15 Scott A. Michaels Pharmaceutical formulations for subcutaneous administration of furosemide
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
HK1226581A1 (zh) * 2014-02-03 2017-09-29 Novartis Ag 用於输液器上的过滤器
EP2946788A1 (en) * 2014-05-23 2015-11-25 Immundiagnostik AG Method and composition for treating heart failure with preserved ejection fraction
KR20170018829A (ko) * 2014-06-13 2017-02-20 노파르티스 아게 Gdf-15를 감소시키기 위한 세렐락신의 용도
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
US11298081B2 (en) 2016-02-12 2022-04-12 Cardiac Pacemakers, Inc. Systems and methods for patient monitoring
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US11832970B2 (en) 2017-07-26 2023-12-05 Cardiac Pacemakers, Inc. Worsening heart failure stratification
CN107335051A (zh) * 2017-08-18 2017-11-10 温州医科大学附属第医院 一种保护慢性心衰肾功能的药物组合物
EP3893843B1 (en) 2018-12-10 2025-07-30 SQ Innovation AG Pharmaceutical compositions of furosemide and uses thereof
WO2020141224A1 (en) 2019-01-04 2020-07-09 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3906020A1 (en) 2019-01-04 2021-11-10 SQ Innovation AG Pharmaceutical compositions of torsemide and uses thereof
MX2021009084A (es) 2019-01-31 2021-10-26 Scpharmaceuticals Inc Formulaciones farmaceuticas liquidas concentradas de furosemida y metodos para administrar las mismas.
CN119947743A (zh) 2022-08-31 2025-05-06 雷拉科斯拉制药有限责任公司 免疫抑制药物及治疗方法
WO2025056188A1 (en) 2023-09-15 2025-03-20 Relaxera Pharmazeutische Gmbh & Co. Kg Relaxin medication

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
ATE241012T1 (de) 1993-06-21 2003-06-15 Genentech Inc Verfahren zur herstellung von humanen relaxin
CA2145515A1 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5760069A (en) 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
US6211147B1 (en) 1995-08-15 2001-04-03 Connetics Corporation Method of promoting angiogenesis using relaxin
DE60128540T2 (de) 2000-02-09 2008-01-31 Bas Medical, Inc., San Mateo Verwendung von relaxin zur behandlung von durch gefässverengung bedingten erkrankungen
DE10155843A1 (de) 2000-11-16 2003-01-30 Immundiagnostik Ag Verfahren zur Prognose und Diagnose von Herzinsuffizienz
US20050113286A1 (en) 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
KR100749857B1 (ko) 2004-03-30 2007-08-16 연세대학교 산학협력단 릴랙신 유전자를 포함하는 유전자 전달 시스템 및 릴랙신을이용한 약제학적 조성물
US20060264367A1 (en) 2005-05-21 2006-11-23 Howard Florey Institute Prevention of fibrosis following cardiac injury
US20080077025A1 (en) 2005-07-11 2008-03-27 Leticia Delgado-Herrera Methods for determining how to treat congestive heart failure
EP2167534B1 (en) 2007-07-12 2012-07-04 Compugen Ltd. Bioactive peptides and method of using same
MX2010012502A (es) 2008-05-16 2011-04-11 Corthera Inc Metodo para el tratamiento de insuficiencia cardiaca cronica.
PT2288373E (pt) * 2008-05-16 2015-10-19 Corthera Inc Método de tratamento da dispneia associado com insuficiência cardíaca aguda

Similar Documents

Publication Publication Date Title
JP2016053040A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY187047A (en) Selective pyy compounds and uses thereof
MX2016006053A (es) Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
EA201690962A1 (ru) Составы
JP2015057451A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN2017000270A1 (en) Use of prg4 as an anti-inflammatory agent
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
PE20181523A1 (es) Tratamiento de lupus nefritis usando laquinimod
JP2016518337A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
MA37455A1 (fr) Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique
UA111599C2 (uk) Композиція каспофунгіну
JP2013166781A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR112017009510A2 (pt) composições compreendendo ciclosporina
BR112015007592A2 (pt) composições de enalapril
RS53515B1 (en) A COMBINED COMPOSITION CONTAINING AS THE ACTIVE INGREDIENT OF L-CARNITIN OR PROPIONYL L-CARNITINE, FOR THE PREVENTION OR TREATMENT OF CHRONIC VENUAL INSUFFICIENCY
MX2016007682A (es) Composicion farmaceutica que comprende ivabradina amorfa.
JP2015516452A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX391191B (es) Composiciones de liberación extendida de onapristona y métodos.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
MD20180049A2 (ro) Compoziţie farmaceutică
NI201200008A (es) Otamixaban para el tratamiento de pacientes con alteración renal y de edad avanzada con infarto de miocardio sin elevación del st
JP2015516451A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG10201903656RA (en) Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor